Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Harrow Health (HROW) stocks in Canada

Learn how to easily invest in Harrow Health stocks.

Harrow Health is a drug manufacturers-specialty & generic business based in the US. Harrow Health stocks (HROW.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.71 – a decrease of 12.66% over the previous week. Harrow Health employs 125 staff and has a trailing 12-month revenue of around $66.9 million.

How to buy shares in Harrow Health

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – HROW – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Harrow Health stock price (NASDAQ:HROW)

Use our graph to track the performance of HROW stocks over time.

Harrow Health shares at a glance

Information last updated 2022-01-24.
Latest market close$6.90
52-week range$6.00 - $12.99
50-day moving average $9.27
200-day moving average $9.15
Wall St. target price$16.13
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.38

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Harrow Health stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Harrow Health price performance over time

Historical closes compared with the close of $6.9 from 2022-01-27

1 week (2022-01-19) -17.95%
1 month (2021-12-24) N/A
3 months (2021-10-28) -28.57%
6 months (2021-07-28) -24.84%
1 year (2021-01-28) -25.61%
2 years (2020-01-28) 3.60%
3 years (2019-01-28) 12.01%
5 years (2017-01-27) 178.23%

Is Harrow Health under- or over-valued?

Valuing Harrow Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Harrow Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Harrow Health's EBITDA

Harrow Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.9 million.

The EBITDA is a measure of a Harrow Health's overall financial performance and is widely used to measure a its profitability.

Harrow Health financials

Revenue TTM $66.9 million
Operating margin TTM 8.96%
Gross profit TTM $34.4 million
Return on assets TTM 4.62%
Return on equity TTM -45.91%
Profit margin -14.11%
Book value $0.62
Market capitalisation $212 million

TTM: trailing 12 months

Harrow Health share dividends

We're not expecting Harrow Health to pay a dividend over the next 12 months.

Have Harrow Health's shares ever split?

Harrow Health's shares were split on a 1:5 basis on 8 February 2013. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Harrow Health shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Harrow Health shares which in turn could have impacted Harrow Health's share price.

Harrow Health share price volatility

Over the last 12 months, Harrow Health's shares have ranged in value from as little as $6 up to $12.99. A popular way to gauge a stock's volatility is its "beta".

HROW.US volatility(beta: 0.87)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harrow Health's is 0.8702. This would suggest that Harrow Health's shares are less volatile than average (for this exchange).

Harrow Health overview

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc. , a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc. , a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site